Abstract
Inflammatory bowel diseases (IBD) are chronic, relapsing, and destructive inflammatory disorders of the gastrointestinal tract. Both Crohn’s disease (CD) and ulcerative colitis (UC) seem to arise from an impaired dialog between the environment and gut microbiota in genetically susceptible hosts, leading to an inappropriate immune activation and resulting in the over-production of pro-inflammatory cytokines.
IL-6 is a key modulator of inflammatory response. It is a phylogenetically important cytokine with relevance in IBD, as well as in other chronic inflammatory diseases and cancer. Influencing the production of this cytokine can change the balance of effector CD4+ T cell subsets and induce B cell antibody production. Moreover, given IL-6 is mostly produced from innate immune cells such as macrophages, neutrophils and mast cells, it is a strategic bridge between the innate and the adaptive system. Interestingly, IL-6 induced signaling can be primarily seen in a relatively small number of IL-6 responsive cells whereas in a chronic phase of inflammation it is able to activate almost all cells of the body through a process known as trans-signaling.
In this review, we discuss the role of IL-6 in chronic inflammation, with particular emphasis on its role in CD and UC, and we explore the potential to develop anti-IL-6 agents for IBD treatment.
Keywords: Biologic therapy, cytokine, Crohn’s disease, monoclonal antibody, pathogenesis, ulcerative colitis.
Current Drug Targets
Title:Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target
Volume: 14 Issue: 12
Author(s): Mariangela Allocca, Manol Jovani, Gionata Fiorino, Stefan Schreiber and Silvio Danese
Affiliation:
Keywords: Biologic therapy, cytokine, Crohn’s disease, monoclonal antibody, pathogenesis, ulcerative colitis.
Abstract: Inflammatory bowel diseases (IBD) are chronic, relapsing, and destructive inflammatory disorders of the gastrointestinal tract. Both Crohn’s disease (CD) and ulcerative colitis (UC) seem to arise from an impaired dialog between the environment and gut microbiota in genetically susceptible hosts, leading to an inappropriate immune activation and resulting in the over-production of pro-inflammatory cytokines.
IL-6 is a key modulator of inflammatory response. It is a phylogenetically important cytokine with relevance in IBD, as well as in other chronic inflammatory diseases and cancer. Influencing the production of this cytokine can change the balance of effector CD4+ T cell subsets and induce B cell antibody production. Moreover, given IL-6 is mostly produced from innate immune cells such as macrophages, neutrophils and mast cells, it is a strategic bridge between the innate and the adaptive system. Interestingly, IL-6 induced signaling can be primarily seen in a relatively small number of IL-6 responsive cells whereas in a chronic phase of inflammation it is able to activate almost all cells of the body through a process known as trans-signaling.
In this review, we discuss the role of IL-6 in chronic inflammation, with particular emphasis on its role in CD and UC, and we explore the potential to develop anti-IL-6 agents for IBD treatment.
Export Options
About this article
Cite this article as:
Allocca Mariangela, Jovani Manol, Fiorino Gionata, Schreiber Stefan and Danese Silvio, Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target, Current Drug Targets 2013; 14 (12) . https://dx.doi.org/10.2174/13894501113146660224
DOI https://dx.doi.org/10.2174/13894501113146660224 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Nanoparticles in Drug Delivery and Regenerative Therapy for Bone Diseases
Current Drug Delivery Mucosal Adjuvants
Current HIV Research Anti-Cancer / Anti-Tumor
Current Bioactive Compounds Current Perspective of COVID-19 on Neurology: A Mechanistic Insight
Combinatorial Chemistry & High Throughput Screening Olive Leaf Extracts Act as Modulators of the Human Immune Response
Endocrine, Metabolic & Immune Disorders - Drug Targets Fc Receptor Signaling in Leukocytes: Role in Host Defense and Immune Regulation
Current Immunology Reviews (Discontinued) A Review of Clinical Studies Assessing the Therapeutic Efficacy of Escitalopram: A Step Towards Development
CNS & Neurological Disorders - Drug Targets Immunomodulatory Actions of Vitamin D Metabolites and their Potential Relevance to Human Lung Disease
Current Respiratory Medicine Reviews Development of Lymphatic Vessels: Tumour Lymphangiogenesis and Lymphatic Invasion
Current Medicinal Chemistry Novel Insights and Therapeutical Applications in the Field of Inhibitors of COX-2
Current Medicinal Chemistry Foreword from the Editor
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Gastric Cytoprotection Beyond Prostaglandins: Cellular and Molecular Mechanisms of Gastroprotective and Ulcer Healing Actions of Antacids
Current Pharmaceutical Design Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Dry Emulsions based on Alpha Cyclodextrin and Vegetable Oils for Buccal Delivery of Lipophilic Drugs
Drug Delivery Letters Melatonin Regulates Angiogenic Factors under Hypoxia in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry How Real is Intention-To-Treat (ITT) Analysis in Non-Interventional Post Authorization Safety Studies? We Can Do Better
Current Drug Safety Ezetimibe and Reactive Oxygen Species
Current Vascular Pharmacology Therapeutic Modulation of Coagulation and Fibrinolysis in Acute Lung Injury and the Acute Respiratory Distress Syndrome
Current Pharmaceutical Biotechnology The Role of Biomarkers to Diagnose Diabetic Foot Osteomyelitis. A Meta-analysis
Current Diabetes Reviews Nanoparticles: A Promising Tool to Promote Reactive Oxygen Species in Cancer Therapy
Current Protein & Peptide Science